Existing backer Banco Sabadell Venture Capital contributed to a round that will help the stroke surgery device developer fund clinical studies.
Legend Capital returned as the RNA drug developer secured $28.8m in a round co-led by Panlin Capital and Trinity Innovation Fund.
Kooksoondang Brewery took part in a series B round for oncology antibody developer Hummingbird Bioscience as it prepares to move its lead assets into the clinic.
Tufts Health Plan, Henry Ford Health System and Highmark Health all chipped in as care provider Kaiser Permanente's corporate VC unit closed its latest fund.
The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.
Pfizer Ventures led the immuno-oncology drug developer's latest round, which included existing backer Boehringer Ingelheim Venture Fund.